RNS Number : 8990A
OptiBiotix Health PLC
29 October 2026

OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")

Release of Video Updates on Investor Hub

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the release of a series of videos on its Investor Hub platform covering the questions most frequently raised by current and prospective shareholders.

OptiBiotix uses its interactive Investor Hub website to bring all OptiBiotix content into a single platform and allows investors to ask questions to provide context on announcements and update on progress whilst remaining compliant with market obligation disclosures.

The Company has carried out a review of questions received and commentary on bulletin boards and prepared a series of videos covering the questions most frequently asked and topics of most interest to investors. These will be released over the next few weeks on the Investor Hub website. If successful it is envisaged this will be a regular occurrence.

The videos will address a range of topics including: progress on the commercialisation of SweetBiotix, the strength of SweetBiotix's commercial proposition compared to existing products, and the value it believes SweetBiotix brings to investors.

The videos will also discuss two private companies, ELO Life systems and Incredo Life systems, who are developing sweet products for agriculture or using silica to improve the sweetness of sugar. These are at a similar stage of development and have raised $40-$60m with valuations reported to be >$100m. These should give investors an indication to the potential value industry places on technologies in this space. The Company believes Sweetbiotix offers substantial advantages over these companies' products in not only being a low-calorie clean sweetener but also a prebiotic fibre offering potential health benefits to an industry which increasingly demands healthy alternatives.

Investors wishing to receive these videos direct by email can sign up for our website here: https://optibiotix.com/auth/signup. All videos will be available after release on the Company's website https://optibiotix.com/ under the News and Media tab.

Stephen O'Hara, Chief Executive Officer, commented:

"Having reported growing sales and increasing margins against a lower cost base for its first-generation products and the growing potential of its holdings in PBX and SBTX, the Company is turning its focus to commercialising SweetBiotix®. This series of videos provides an update to investors on commonly asked questions and new market insight on competitor products which give an indication as to the potential value of SweetBiotix to the industry, and shareholders. With improved flavour profile over existing products, simplified manufacture, and structural analysis indicating a clear regulatory pathway there is growing confidence in the commercial potential of SweetBiotix in an industry needing a healthier alternative to sugar."

Ends

Engage with the OptiBiotix management team directly by asking questions, watching video summaries and seeing what other shareholders have to say.

Subscribe to the new website to get regular updates here: https://optibiotix.com/auth/signup

For further information, please contact: OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAKZMZGFRLGVZZ